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Abstract
Methamphetamine (METH) is an illicit drug which is neurotoxic to the mammalian brain. Numerous studies have revealed
significant decreases in dopamine and serotonin levels in the brains of animals exposed to moderate-to-large METH doses
given within short intervals of time. In contrast, repeated injections of small nontoxic doses of the drug followed by a
challenge with toxic METH doses afford significant protection against monoamine depletion. The present study was
undertaken to test the possibility that repeated injections of the drug might be accompanied by transcriptional changes
involved in rendering the nigrostriatal dopaminergic system refractory to METH toxicity. Our results confirm that METH
preconditioning can provide significant protection against METH-induced striatal dopamine depletion. In addition, the
presence and absence of METH preconditioning were associated with substantial differences in the identity of the genes
whose expression was affected by a toxic METH challenge. Quantitative PCR confirmed METH-induced changes in genes of
interest and identified additional genes that were differentially impacted by the toxic METH challenge in the presence of
METH preconditioning. These genes include small heat shock 27 kD 27 protein 2 (HspB2), thyrotropin-releasing hormone
(TRH), brain derived neurotrophic factor (BDNF), c-fos, and some encoding antioxidant proteins including CuZn superoxide
dismutase (CuZnSOD), glutathione peroxidase (GPx)-1, and heme oxygenase-1 (Hmox-1). These observations are consistent,
in part, with the transcriptional alterations reported in models of lethal ischemic injuries which are preceded by ischemic or
pharmacological preconditioning. Our findings suggest that multiple molecular pathways might work in tandem to protect
the nigrostriatal dopaminergic pathway against the deleterious effects of the toxic psychostimulant. Further analysis of the
molecular and cellular pathways regulated by these genes should help to provide some insight into the neuroadaptive
potentials of the brain when repeatedly exposed to drugs of abuse.
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Introduction
METH (also nicknamed crank, crystal, speed) is an illicit drug
whose abuse prevalence has reached greater proportion than the
combined use of heroin and cocaine in the world. The clinical
history of METH abuse is characterized by the user initially taking
small doses of the drug followed by consumption of progressively
larger doses of the psychostimulant [1,2]. Patients who take these
large doses often suffer from a number of psychiatric disorders
which include paranoia, psychosis, withdrawal-associated depres-
sion, and even suicidal ideations and/or completed suicides [3].
Neuropsychological tests have also revealed significant cognitive
deficits in a majority of METH addicts [3,4]. Evidence for
METH-induced structural changes in humans has also accumu-
lated [5,6]. Several studies have documented decreases in
dopamine [7] and of serotonin (5-HT) [8] transporters in various
regions of the brain. Although some of these neuropathological
changes have been replicated in animal models, their role in the
clinical course of METH abuse disorders remains to be clarified
[2,3,9].
Studies conducted in the 1970’s were the first ones to document
significant decreases in the levels in DA in the brain of nonhuman
primates that had been exposed to repeated injections of METH
and sacrificed two weeks after cessation of drug exposure [10].
Subsequent studies in rodents replicated these observations and
revealed that METH could cause substantial decreases in DA, 5-
HT, and other markers of the integrity of monoaminergic systems
in various brain regions [11–14]. The majority of these
publications used models where moderate to large doses of
METH were injected within short intervals of time and/or during
single-day binges [2,15]. Because single-day METH binges are
more representative of accidental overdoses by inexperienced
users, several groups have experimented with injecting increasing
METH doses over several days prior to challenging the animals
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patterns of drug administration, which we recently entitled METH
preconditioning [18], provide substantial attenuation of the toxic
effects on monoaminergic systems, the involved neuroprotective
mechanisms have remained mysterious.
Several groups of investigators have suggested that METH
pretreatment might cause inhibition of METH-induced changes in
body temperature, vesicular DA uptake, free radical production,
and microglial activation [16,19,20] since these are involved in the
acute toxic effects of the drug [2]. Nevertheless, much remains to
be done in order to identify the molecular pathways involved in
the neuroprotection mediated by METH preconditioning. Be-
cause the protective effects of METH preconditioning might be
related to transcriptional changes similar to those observed in
other models of brain preconditioning [21–27], the present study
was conducted to examine if METH preconditioning might be
associated with differential gene expression in the rat midbrain
area that encompasses the substantia nigra (SN), a region whose
neuronal cell bodies send dopaminergic axons into the rat
striatum, a brain region which is injured by toxic METH doses
[2]. Identification of these genes might help to decipher molecular
mechanisms of protection against METH-induced injuries. These
genes might also provide a more systematic rationale for the
development of better therapeutic approaches against METH
addiction and toxicity.
Results
Effects of METH on monoamine levels in the rat brain
Fig. 1 shows the effects of METH on the levels of DA, DOPAC,
5-HT, and 5-HIAA in the striatum of the animals treated with
METH as described in Table S1 provided as supplemental data.
Briefly, animals were injected with saline or increasing doses of
METH and then challenged 72 hours later with saline or a toxic
dose of METH (5 mg/kg68 injections, given one hour apart).
This paradigm resulted in four groups of animals: saline/saline
(SS), saline/METH (SM), METH/saline (MS), and METH/
METH (MM) [12,18]. METH preconditioning alone (MS group)
did not cause any significant changes in monoamine levels in
comparison to saline control group (SS group). The METH
challenge caused significant decreases (263%) in DA levels in the
striatum of rats pretreated with saline (SM group) (Fig. 1A).
However, the METH challenge caused no significant decreases in
DA levels in the METH-preconditioned (MM) group in
comparison to the SS or the MS group. In addition, DA levels
in the MM group were significantly higher than those measured in
the SM group (Fig. 1A). METH challenge also caused significant
decreases in DOPAC (244%) (Fig. 1B) but not in HVA (data not
shown) levels in the SM group. Pretreatment with METH
provided complete protection against the toxic effects of the
METH challenge on DOPAC levels (compare MM group to SM
group) (Fig. 1B).
The acute METH challenge also caused substantial decreases in
striatal 5-HT concentrations in the saline- (253%) and METH-
pretreated (224%) rats (Fig. 1C). METH pretreatment provided
some degree of protection against reductions in 5-HT levels in
drug-challenged animals (compare MM to SM group). 5-HIAA
levels showed non-significant changes in the SM group (Fig. 1D).
These small decreases were prevented by METH preconditioning
(compare SM to MM group) (Fig. 1D).
Figure 2 shows the effects of METH on the concentrations of
DA, DOPAC, 5-HT, and 5-HIAA in a region of the ventral
Figure 1. METH preconditioning causes protection against METH-induced depletion of monoamines in the rat striatum. The animals
were injected as described in Table S1 and euthanized at 24 hours after the last injection of the saline or METH challenges. Values are expressed as
means 6 SEM (n=6-* animals per group). Keys to statistics: *, **, ***=p,0.05, 0.01, 0.001, respectively, in comparison to the SS group; #, ##,
###=p,0.05, 0.01, 0.001, respectively, in comparison to the MS group; !, !!=p,0.05, 0.01, respectively, in comparison to the SM group.
doi:10.1371/journal.pone.0007812.g001
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ventral tegmental area (VTA). Neither METH preconditioning
alone nor the METH challenge caused any significant changes in
the levels of DA (Fig. 2A) or DOPAC (Fig. 2B) in the SN/VTA
area. In contrast, METH injections induced significant decreases
in 5-HT levels in both saline- and in METH-pretreated rats
(Fig. 2C). However, METH did not cause any changes in 5-HIAA
levels in any of the two pretreatment groups (Fig. 2D).
Identification of genes regulated by METH
preconditioning and by METH challenges in the ventral
midbrain area
Microarray analysis has become an important tool in toxico-
logical research because it allows investigators to obtain a better
panoramic view of drug-induced transcriptional changes after
exposure to pharmacological agents and toxins [28,29]. In order to
assess transcriptional effects of toxic doses of METH in the ventral
midbrain of rats pretreated with saline or METH, we used
Illumina RatRef-12 Expression BeadChips arrays that contain 22,
523 probes (Illumina Inc., San Diego, CA). The complete raw
microarray data have been submitted to the NCBI GEO database:
Accession number GSE17665. The Venn diagram in Figure 3
shows the results of 3 comparisons between the four groups of rats:
MS vs SS, SM vs SS, and MM vs MS. To be identified as
changed, the genes had to meet the following criteria: 1.7-fold
changes at p,0.05. A total of 238 showed differential expression
in the comparisons that included METH preconditioning alone
and toxic METH challenges in the presence or absence of METH
preconditioning (see Tables 1–3 for lists of the genes). The METH
preconditioning alone caused changes in the expression of 63
genes, with 20 being upregulated and 43 being downregulated
Figure 2. The METH challenge caused serotonin depletion in the ventral midbrain of the rat. The animals were pretreated and
challenged with METH or saline as shown in Table S1 and euthanized at 24 hours after the last injection. Keys to statistics are shown in legend to
Fig. 1.
doi:10.1371/journal.pone.0007812.g002
Figure 3. METH preconditioning reconditions midbrain tran-
scriptional responses to METH binge challenges. The Venn
diagram shows the overlap of genes identified in the three
comparisons. The animals were injected and killed as described above.
RNA was extracted from midbrain tissues from the side contralateral to
the one used to measure monoamines. Microarray experiments were
performed as described in the method section. Genes were identified as
significantly changed if they show greater than 61.7-fold changes at
p,0.05.
doi:10.1371/journal.pone.0007812.g003
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epigenetic control, neurotransmission/signal transduction, and
transcription regulation. Interestingly, several synaptic vesicle
proteins including synaptogyrin 4, synaptotagmin II and synapto-
physin-like 2 [30] are significantly downregulated after chronic
administration of METH. The toxic METH challenge caused
changes in a total of 100 genes in the absence of METH
preconditioning (SM group), with 50 being upregulated and 50
being downregulated (Table 2). These fall within classes of genes
involved in metabolism, neurotransmission/signal transduction,
proteolysis, responses to various physiological stresses, and
transcription control. As expected, the changes in gene expression
in animals euthanized 24 hours after the last injection of METH
are different from those observed in animals sacrificed at 2 or
4 hours after METH injections that identified changes in
immediate early genes (IEGs), several transcription factors, and
in genes involved in endoplasmic reticulum stress [31–33]. The
toxic METH challenge caused differential expression in 95 genes
in the METH preconditioned group (MM), with 70 being
upregulated and 25 being downregulated (Table 3). These
transcripts represent classes of genes that are involved in the
control of epigenetic modifications including histone H2ao,
neurotransmission/signal transduction such as thyrotropin releas-
ing hormone (TRH), and stress responses including heat shock
Table 1. Effects of METH preconditioning alone on gene expression in the ventral midbrain.
Genbank Symbol Gene Name MS/SS
Epigenetics
XM_344599 Hist1h2ao histone 1, H2ao 22.04
NM_001106371 Hells helicase, lymphoid specific 240.47
Metabolism and Catabolism
XM_230581 Acoxl acyl-Coenzyme A oxidase-like 17.92
NM_001025402 Umps uridine monophosphate synthetase 22.32
NM_031598 Pla2g2a phospholipase A2, group IIA (platelets, synovial fluid) 264.48
Neurotransmission/Signal Transduction
NM_001001023 Olr94 olfactory receptor 94 16.34
NM_001000409 Olr855 olfactory receptor 855 1.81
NM_001007557 Emr1 EGF-like module containing, mucin-like, hormone receptor-like 1 21.70
NM_001000129 Olr62 olfactory receptor 62 21.84
NM_012665 Syt2 synaptotagmin II 21.84
NM_012627 Pkib protein kinase (cAMP-dependent, catalytic) inhibitor beta 21.94
NM_001025644 Syngr4 synaptogyrin 4 22.01
NM_001000915 Olr790 olfactory receptor 790 22.34
XM_001068241 Eda2r ectodysplasin A2 receptor 22.72
NM_001109144 Pth2 parathyroid hormone 2 24.15
NM_001009487 Ly49s4 Ly49 stimulatory receptor 4 27.38
NM_080773 Chrm1 cholinergic receptor, muscarinic 1 211.13
NM_001107800 Stk4 serine/threonine kinase 4 216.69
NM_001107188 Rasal2 RAS protein activator like 2 217.36
NM_001001017 Olr1143 olfactory receptor 1143 218.65
NM_001005384 Osmr oncostatin M receptor 222.22
NM_001108563 Sypl2 synaptophysin-like 2 222.29
NM_001081444 Pik3r6 phosphoinositide-3-kinase, regulatory subunit 6 222.94
Transcription/Transcription Factors/Nucleotide Binding
NM_052802 Kap kidney androgen regulated protein 29.67
XM_342933 Gpatch3 G patch domain containing 3 15.80
NM_022857 N5 DNA binding protein N5 21.80
NM_001106375 Papss2 39-phosphoadenosine 59-phosphosulfate synthase 2 21.85
NM_001108953 Zbtb6 zinc finger and BTB domain containing 6 22.37
NM_001137626 E2f3 E2F transcription factor 3 225.45
NM_001107170 Tcfcp2l1 transcription factor CP2-like 1 226.76
NM_001105863 Thap7 THAP domain containing 7 234.62
The data in this table were generated from the comparisons between the METH preconditioning alone (MS group) and saline control group (SS group) of animals
euthanized at 24 h. To be identified as changed, the genes had to meet the criteria: greater or less than 1.7-fold and p,0.05. The values represent fold changes
between the specified groups (n=4 per group). The genes are listed in descending order according to the METH-induced fold changes within their specific functional
classification.
doi:10.1371/journal.pone.0007812.t001
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Genbank Symbol Gene Name SM/SS
Epigenetics
NM_001108060 Rcor1 REST/NRSE corepressor 1 29.50
Metabolism and Catabolism
XM_001075890 Foxred2 FAD-dependent oxidoreductase domain containing 2 4.76
XM_001074061 Mthfr 5,10-methylenetetrahydrofolate reductase 3.08
NM_053962 Sds serine dehydratase 3.05
NM_001004077 Gk2 glycerol kinase 2 2.23
NM_001109022 Inmt indolethylamine N-methyltransferase 2.00
NM_053896 Aldh1a2 aldehyde dehydrogenase 1 family, member A2 1.79
NM_031834 Sult1a1 sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 1.78
NM_001105899 Liph lipase, member H 21.72
NM_031010 Alox15 arachidonate 15-lipoxygenase 22.68
NM_012496 Aldob aldolase B 23.40
XM_001068364 Akr1c12 aldo-keto reductase family 1, member C12 231.03
Neurotransmission/Signal Transduction
NM_001106879 Efhb EF hand domain family, member B 55.87
NM_001107909 Map3k6 mitogen-activated protein kinase kinase kinase 6 40.00
NM_001044250 Stat6 signal transducer and activator of transcription 6 21.74
NM_001008932 V1rg17 vomeronasal 1 receptor, G17 21.65
NM_031649 Klrg1 killer cell lectin-like receptor subfamily G, member 1 17.70
NM_001107726 Rrh retinal pigment epithelium derived rhodopsin homolog 16.92
XM_001066511 Pdzd3 PDZ domain containing 3 7.41
NM_012835 Cort cortistatin 4.41
NM_001108975 Ptch1 patched homolog 1 2.37
NM_138505 Adra2b adrenergic, alpha-2B-, receptor 2.24
XM_001080694 Ccdc155 coiled-coil domain containing 155 1.96
NM_057115 Ptpn12 protein tyrosine phosphatase, non-receptor type 12 1.75
NM_001033064 Kazald1 Kazal-type serine peptidase inhibitor domain 1 21.73
NM_001000782 Olr1414 olfactory receptor 1414 21.74
NM_031766 Cpz carboxypeptidase Z 21.75
XM_232745 Sfn stratifin 21.78
NM_001008513 Ccl21b chemokine (C-C motif) ligand 21b (serine) 21.93
NM_001106894 Gpr110 G protein-coupled receptor 110 21.99
NM_012770 Gucy1b2 guanylate cyclase 1, soluble, beta 2 22.03
NM_001106123 Mrc1 mannose receptor, C type 1 22.11
NM_001000268 Olr1673 olfactory receptor 1673 22.12
NM_001000132 Olr49 olfactory receptor 49 22.40
NM_022202 Grm8 glutamate receptor, metabotropic 8 23.06
NM_181373 Grik3 glutamate receptor, ionotropic, kainate 3 26.13
NM_001107625 Plekhk1 pleckstrin homology domain containing, family K member 1 Rtkn2 rhotekin 2 212.91
NM_001000884 Olr1117 olfactory receptor 1117 217.92
NM_012609 Nf1 neurofibromin 1 224.98
NM_001001017 Olr1143 olfactory receptor 1143 241.75
NM_001000151 Olr113 olfactory receptor 113 274.45
Stress Responses
NM_057194 Plscr1 phospholipid scramblase 1 5.43
NM_001109577 Derl3 Der1-like domain family, member 3 2.27
NM_001007729 Pf4 platelet factor 4 21.76
NM_019335 Eif2ak2 eukaryotic translation initiation factor 2-alpha kinase 2 22.15
NM_133624 Gbp2 guanylate nucleotide binding protein 2 22.39
METH and Neuroadaptations
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namely olfactory receptor 1143 and ribosomal protein L36a, were
common among the three sets of comparisons (Fig. 3). They were
both downregulated in the MS/SS and SM/SS comparisons but
upregulated in the MM/MS comparison (see Tables 1–3).
One interesting observation among the response profiles occurs
between the saline- and METH-pretreated rats after injections of
toxic doses of METH. The Venn diagram showed that only 7
genes overlapped between these two sets of comparisons (Fig. 3).
These include interferon regulatory factor 7 (Irf7), matrix
metallopeptidase 14 (Mmp14), mitogen-activated protein kinase
kinase kinase 6 (Map3k6), olfactory receptor 1143 (Olr1143),
parvin beta (parvinb), and ribosomal protein L36a (Rpl36a), The
observation of very few overlapping genes suggests that transcrip-
tional responses to a METH challenge in the presence and
absence of METH preconditioning are very dissociable (compare
the list of genes in Tables 2 and 3). In fact, although some of them
fell within similar classifications, as noted above, there were
marked differences in the identity of the METH-regulated genes in
the absence and presence of METH preconditioning. For
example, there was no overlap in the genes listed under classes
of epigenetics, metabolism and catabolism, responses to stress, or
cellular transport. Moreover, of the overlapped genes, Irf7,
Mmp14, and Parvb were downregulated after the METH
challenge in both the absence and presence of METH precondi-
tioning, Map3k6 was upregulated in both cases, whereas Olr1143
and Rpl36a were downregulated or upregulated in the respective
absence or presence of METH pretreatment. One possibility for
these differences is that the METH challenge caused increased
expression of the repressor element silencing transcription factor/
neuronal restrictive silencer factor (REST/NRSF) [34,35] core-
pressor 1 (Rcort1) in the absence of METH preconditioning (see
Table 3). The REST corepressor acts together with REST to
silence the expression of many genes [35] which represent various
functional groups including ion channels, metabolism, neurotrans-
mitter receptors, and intracellular signaling [36]. Thus, METH-
induced upregulation of this co-repressor might be responsible, in
part, for the larger number of genes that are downregulated in the
SM in contrast to the MM group (compare Table 2 to Table 3).
Quantitative PCR
We used quantitative PCR to validate the expression of some of
the genes identified by the microarray analyses using RNA from
individual animals from the four groups. The primers are listed in
Table 4. We first confirmed the METH-induced changes in the
expression of HspB2 [37,38] which is a member of the family of
small heat shock proteins (sHSPs) that have been shown to exert
significant protective effects in models of neurodegeneration
[39,40]. As seen in Fig. 4A, the METH challenge caused
significant changes in HspB2 expression in both the presence
and absence of METH preconditioning, with the increases in the
METH preconditioned group being of greater magnitude. HspB2
is localized in the mitochondria and protects cells against heat-
mediated cell demise [41]. Experiments using knockout mice have
shown that HspB2 can protect against ischemia/reperfusion-
induced injuries in the heart [42], suggesting that the METH-
induced changes in HspB2 might participate in preventing
retrograde degeneration of the nigrostriatal dopaminergic system
in rodents after METH-induced destruction of striatal DA
terminals.
We also sought to confirm the METH-induced changes in the
expression of thyrotropin-releasing hormone (TRH) observed in
the microarray data because TRH is widely distributed in the rat
brain [43] and interacts with dopaminergic systems in the brain
[44]. Our results confirmed that the METH challenges caused
substantial increases in TRH expression in the presence of METH
preconditioning (Fig. 4B). There were also METH-induced
changes in the saline-pretreated rats, increases that were of
smaller magnitude than those observed in the presence of METH
preconditioning. The small increases observed in the SM group
are consistent with increases in TRH concentrations previously
reported in the brains of rats that had received doses of the
neurotoxin, 6-hydroxydopamine (6-OHDA), which depletes DA in
the brain [45] since the SM group also experiences significant
decreases in striatal DA levels (see Fig. 1A). The fact that METH-
challenged METH-preconditioned animals, which were protected
against striatal DA depletion (MM group in Fig. 1A), showed
greater increases in TRH expression than the saline-pretreated
METH-challenged rats suggests that the changes in the TRH
Genbank Symbol Gene Name SM/SS
NM_182952 Cxcl11 chemokine (C-X-C motif) ligand 11 24.90
NM_012725 Klkb1 kallikrein B, plasma 1 2103.20
Transcription/Transcription Factors/Nucleotide Binding
XM_220520 Rai1 retinoic acid induced 1 33.78
NM_145767 Prrxl1 paired related homeobox protein-like 1 2.69
NM_017058 Vdr vitamin D (1,25- dihydroxyvitamin D3) receptor 2.15
NM_001104612 Jrk jerky homolog (mouse) 1.98
XM_216941 Matn2 matrilin 2 1.90
NM_001033691 Irf7 interferon regulatory factor 7 21.88
XM_341433 Ccdc111 coiled-coil domain containing 111 21.95
NM_001107281 Klf12 Kruppel-like factor 12 22.96
NM_053520 Elf1 E74-like factor 1 216.05
The data in this table were generated from the comparisons between the saline-pretreated challenged with METH (SM group) and saline control group (SS group) of
animals euthanized at 24 h. To be identified as changed, the genes had to meet the criteria: greater or less than 1.7-fold and p,0.05. The values represent fold changes
between the specified groups (n=4). The genes are listed in descending order according to the METH-induced fold changes within their specific functional
classification.
doi:10.1371/journal.pone.0007812.t002
Table 2. Cont.
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Genbank Symbol Gene Name MM/MS
Epigenetics
XM_001052969 Tert telomerase reverse transcriptase 15.60
XM_344599 Hist1h2ao histone 1, H2ao 1.76
Metabolism and Catabolism
NM_001024321 Hyal5 hyaluronoglucosaminidase 5 21.41
NM_001012080 Hfe2 hemochromatosis type 2 (juvenile) (human homolog) 3.40
NM_001031656 Serinc2 serine incorporator 2 3.09
NM_001025402 Umps uridine monophosphate synthetase 2.92
NM_022926 Galnt7 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7 (GalNAc-T7) 2.06
NM_173308 Fut11 fucosyltransferase 11 2.03
NM_173303 Cox6c1 cytochrome c oxidase subunit VIc-1 1.81
XM_227543 Man1a2 mannosidase, alpha, class 1A, member 2 1.77
NM_031582 Aoc3 amine oxidase, copper containing 3 (vascular adhesion protein 1) 21.99
XM_230581 Acoxl acyl-Coenzyme A oxidase-like 217.93
Neurotransmission/Signal Transduction
XM_345342 C5 complement component 5 48.31
NM_172328 Tac4 tachykinin 4, Preprotachykinin C 35.59
NM_017123 Areg amphiregulin 33.33
NM_001001017 Olr1143 olfactory receptor 1143 16.34
NM_019630 Gip gastric inhibitory polypeptide 16.31
XM_341088 Rasal1 RAS protein activator like 1 15.24
NM_001009967 Pip5k1c phosphatidylinositol-4-phosphate 5-kinase, type I, gamma 13.72
NM_001001026 Olr127 olfactory receptor 127 13.23
XM_343640 Ptprm protein tyrosine phosphatase, receptor type, M 13.16
XM_343881 Havcr2 hepatitis A virus cellular receptor 2 12.97
NM_001107909 Map3k6 mitogen-activated protein kinase kinase kinase 6 10.03
NM_013046 Trh thyrotropin releasing hormone 4.22
NM_022714 Crhr2 corticotropin releasing hormone receptor 2 3.02
NM_058208 Socs2 suppressor of cytokine signaling 2 2.52
NM_139188 Otos otospiralin 2.35
XM_001058249 Fcrl1 Fc receptor-like 1 2.03
XM_001055537 Rhbdl2 rhomboid, veinlet-like 2 (Drosophila) 1.98
XM_001075502 Ms4a11 membrane-spanning 4-domains, subfamily A, member 11 1.90
XM_213380 Rilp Rab interacting lysosomal protein 1.78
NM_021684 Adcy10 adenylate cyclase 10 (soluble) 21.97
NM_001108321 Rtp4 receptor transporter protein 4 22.02
XM_344047 Olr1571 olfactory receptor 1571 24.34
NM_133413 Cysltr2 cysteinyl leukotriene receptor 2 212.54
NM_001000146 Olr105 olfactory receptor 105 220.33
Stress Responses
NM_212488 Btnl7 butyrophilin-like 7 164.20
NM_130431 Hspb2 heat shock protein 2 14.03
XM_574098 Mtcp1 mature T-cell proliferation 1 1.70
XM_001057564 Csf3r colony stimulating factor 3 receptor (granulocyte) (Csf3r) 21.81
NM_145672 Cxcl9 chemokine (C-X-C motif) ligand 9 23.58
Transcription/Transcription Factors/Nucleotide Binding
XM_224295 Zc3h13 zinc finger CCCH type containing 13 34.01
NM_207611 Bhlhb9 basic helix-loop-helix domain containing, class B, 9 26.74
NM_031803 Gmeb2 glucocorticoid modulatory element binding protein 2 25.77
NM_001109237 Neurod6 neurogenic differentiation 6 2.54
METH and Neuroadaptations
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protecting the cell bodies located in the SN/VTA area but also in
protecting striatal dopaminergic terminals against METH-induced
DA depletion.
As shown in Fig. 4C, we were also able to confirm the METH-
induced increases in Pip5k1c, also called PIP5KIgamma [46]. The
METH challenge caused increases only in the METH precondi-
tioned state. Pip5k1c is a major synaptic type I phosphatidylinositol
4-phosphate (PtdIns(4)P) 5-kinase (PIP5K) that phosphorylates
phosphatidylinositol-4-phosphate to generate phosphatidylinositol
4, 5-bisphosphate (PIP2), a lipid molecule that has been implicated
in an array of cellular functions which include signal transduction,
cytoskeletal organization, regulated exocytosis and clathrin-medi-
ated endocytosis [47–50]. Because PIP2 is also involved in the
mediation of gene expression and cell survival [51,52], the present
results suggest that METH preconditioning might have induced
changes in lipid signaling, which might participate in the alterations
of METH-induced transcriptional responses of the SN/VTA cell
bodies. Because PIP5K function is regulated mostly through protein
interactions with Rho and Arf families of small G-proteins [53], it
was surprising that METH preconditioning was associated with
increased Pip5k1c transcription in response to a toxic METH
challenge. Elucidation of the mechanism involved and the role of
Pip5k1c in the function of the mesostriatal dopaminergic system in
the absence and presence of METH preconditioning will have to
await future studies. This is an important issue because PIP5KI-
gamma is the major PIP kinase identified at synapses [54] and
because it has recently been shown to be required for neuronal
development [55].
We also confirmed METH-induced increases in Ptprm in the
presence of METH preconditioning (Fig. 4D). We also found that
the METH challenge caused smaller increases in the saline-
Genbank Symbol Gene Name MM/MS
XM_215728 Hltf helicase-like transcription factor 2.41
NM_001037216 Nxf7 nuclear RNA export factor 7 21.74
NM_139186 Mki67ip spermatogenesis-related protein 21.84
XM_001058675 Rorc RAR-related orphan receptor C 21.93
XM_221915 Zfp853 zinc finger protein 853 22.02
NM_053468 Rag1 recombination activating gene 1 22.12
NM_001033691 Irf7 interferon regulatory factor 7 22.74
NM_001025729 Zbed3 zinc finger, BED domain containing 3 26.25
The data in this table were generated from the comparisons between the METH preconditioning treated with METH (MM group) and METH preconditioning alone (MS
group) of animals euthanized at 24 h. To be identified as changed, the genes had to meet the criteria: greater or less than 1.7-fold and p,0.05. The values represent fold
changes between the specified groups (n=4). The genes are listed in descending order according to the METH-induced fold changes within their specific functional
classification.
doi:10.1371/journal.pone.0007812.t003
Table 4. List of Primers.
Primer Name Primer Up Primer Down
HspB2 CTG CCG AGT ACG AAT TTG CC CTC TGG CTA TCT CTT CCT CTT
TRH GGA CAA GTA TTC ATG GGC CTC TTG GTG ACA TCA GAC
Pip5K1c GCC TCT GAT GAG GAA GAT GC AGT TAT GTG TCG CTC TCG CC
Ptprm TCA TCG ACC CAA CCA TTA T CCA GTA TTT GCA GCA TTT C
c-fos GGG CAA AGT AGA GCA G CTC TTT CAG TAG ATT GGC A
Fra1 TGT GCC AAG CAT CAA C CCA ACT TGT CGG TCT C
Fra2 CTG TGT GCA AAA TCA GT AGC AAT GCT AAT GGG C
c-Jun TTG CCC CAA CAG ATC C GCT GCG TTA GCA TGA G
JunB CAC GAC TAC AAA CTC C CGT GGT TCA TCT TCT G
JunD GTG TGT TTC CTT GTG TTG TTT GGC GTA ACG AAG AC
BDNF TGA TGC TCA GCA GTC AA CAC TCG CTA ATA CTG TCA C
GDNF GGA CTC TAA GAT GAA GTT ATG G ATC AAA CTG GTC AGG ATA AT
CuZnSOD AAT ACA CAA GGC TGT ACC GAG ATC ACA CGA TCT TCA A
MnSOD AAC TGG GAG AAT GTT AGC TGG ATA GGC ATC AAT GAA GAT TA
GPx-1 TGT TTG AGA AGT GCG AG TCC AGG AAA TGT CGT TG
Hmox-1 GTA CCA TAT CTA CAC GGC GGA GAC GCT TTA CAT AGT
18s GCG CAA ATT ACC CAC T ATC CAA CTA CGA GCT T
doi:10.1371/journal.pone.0007812.t004
Table 3. Cont.
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phosphatases which are involved in tyrosine phosphorylation/
dephosphorylation events that are controlled by protein tyrosine
kinases (PTKs) and protein tyrosine phosphatases (PTPs) [56–58].
This process is critical to the regulation of several cellular functions
including cell proliferation and differentiation, metabolism, and
gene transcription [58]. Ptprm mediates aggregation through
homophilic binding [59] and associates with cadherins [60] which
are a large family of cell-cell adhesion molecules that bind actin
and intermediate filaments to the plasma membrane and play
significant roles in synaptic plasticity [61]. Thus, increased Ptprm
expression in the presence of METH preconditioning might
constitute one component of molecular events involved in long-
term neuroadaptations to repeated METH injections. This idea is
consistent with reports of psychostimulant-induced structural
plasticity in animals exposed to psychostimulants [62].
Microarray analyses may sometimes underestimate changes in
gene expression [63]. Therefore, we quantified the expression of
some members of the AP1 transcription factors (TFs) which have
been implicated in brain preconditioning [64,65] and are affected
in several regions of the rodent brain early after METH
administration [31,32,66,67]. We thought it possible that there
might be differential expression of these factors in the METH
preconditioning model even though they were not identified in the
microarray experiments. Fig. 5 shows the effects of the toxic
METH challenge in the absence and presence of METH
preconditioning. There were significant increases in c-fos expres-
sion in the METH-challenged preconditioned group in compar-
ison to all three groups (Fig. 5A). The METH-challenged saline-
pretreated group did not show any significant changes in c-fos.
Fra1 expression showed significant METH challenge-induced
increases in the absence of METH preconditioning whereas the
increases in the MM group did not reach statistical significance
(Fig. 5B) There were significant increases in Fra2 expression in the
SM group in comparison to both the SS and the MS group
whereas the increased observed in the MM group were
significantly different from the MS group (Fig. 5C). We also
measured the expression of c-jun, junB, and junD in the four
groups. There were no significant different differences in c-jun
expression in any of the groups (Fig. 5D). METH caused
significant increases only in the METH preconditioned state
(Fig. 5E). JunD expression was affected by METH only in the
absence of METH preconditioning (Fig. 5F).
We also measured the expression of brain derived neurotrophic
factor (BDNF) which is thought to be a mediator of ischemic
preconditioning [64,65,68,69] and of glial cell line-derived
neurotrophic factor (GDNF) which is known to exert protective
effects against METH-induced toxicity [70–72]. Both of these
trophic factors are involved in the survival of midbrain
dopaminergic neurons [73–76]. Fig. 6A shows that the toxic
METH challenge caused significant increases in BDNF in the
presence of METH preconditioning. The small increase in BDNF
in the SM group was not significantly different from the SS group
but was different from the MS group. In contrast, there were
smaller changes in the expression of GDNF after the METH
challenge in the presence and absence of METH preconditioning,
Figure 4. Quantitative PCR validates METH challenge-induced changes in gene expression in the METH-preconditioned group. Data
were obtained from RNA obtained from 5–6 animals per group and measured individually. The mRNA levels were normalized to 18S rRNA levels. The
values represent means + SEM in comparison to the saline-pretreated challenged with saline (SS group). METH caused substantial increases in (A)
HspB2 in the MM group, (B) TRH in the SM and MM groups, (C) Pip5k1c in the MM group, and (D) Ptprm in both the SM and MM groups. Keys to
statistics: *, **, ***=p,0.05, 0.01, 0.001, respectively, in comparison to the SS group; #, ##, ###=p,0.05, 0.01, 0.001, respectively, in comparison
to the MS group; !, !!, !!!=p,0.05, 0.01, 0.001 respectively, in comparison to the SM group.
doi:10.1371/journal.pone.0007812.g004
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group (Fig. 6B).
Finally, we measured the expression of several antioxidant genes
that have been proposed as potential mediators of ischemic
preconditioning [64,77,78] because METH toxicity involves the
production of reactive oxygen species [2,79]. These include the
antioxidant enzymes copper zinc superoxide dismutase (CuZn-
SOD), manganese SOD (MnSOD), and glutathione peroxidase-1
(GPx1). These were chosen because METH-induced toxicity is
mediated, in part, by the production of reactive oxygen species
(ROS) such as superoxides [80], hydrogen peroxide (H2O2)
[81,82] and hydroxyl radicals (see [2] for a recent review). We
Figure 6. The METH challenge caused increases in BDNF expression in the rat ventral midbrain in the presence of METH
preconditioning. The METH challenge caused significant increases in (A) BDNF mRNA in the METH-preconditioned group (MM). The METH-induced
changes in (B) GDNF were only significantly different from the values in the MS but not from the other groups. Keys to statistics are as in Fig. 4.
doi:10.1371/journal.pone.0007812.g006
Figure 5. The METH challenge caused differential responses in the expression of AP1 transcription factors in the presence and
absence of METH preconditioning. METH caused substantial increases in (A) c-fos in the MM group, (B) Fra1 in the SM group, and (C) Fra2 in the
SM and MM groups. (D) c-Jun expression was not affected in any of the groups whereas (E) JunB showed METH-induced increases in the MM while (F)
JunD expression was increased in the SM group. Keys to statistics are as described in Fig. 4.
doi:10.1371/journal.pone.0007812.g005
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differential responses to the METH challenge in the presence and
absence of METH preconditioning. Fig. 7A shows that the
METH challenge caused small but significant increases in
CuZnSOD mRNA levels in the MM in comparison to the SS
and MS groups. The SM group showed small increases that did
not reach significance. The expression of MnSOD was also
significantly increased in the MM group (Fig. 7B). The METH-
induced changes in the SM group did not reach significance. GPx-
1 showed significant increases in the MM group but not in the SM
group (Fig. 7C). We also measured the levels of Hmox-1 which is
induced by toxic METH doses [33] and which was recently
reported to protect against METH toxicity [83]. As can be seen in
Fig. 7D, there were significant METH challenge-induced increases
in Hmox-1 expression in the presence of METH preconditioning.
The increases in the SM did not reach significance due to some
individual variability in the response to METH in that group.
Discussion
The major findings of our study are that a challenge with toxic
doses of METH caused marked reductions in the levels of DA and
5-HT in the striatum but significant decreases only in 5-HT
concentrations in the VTA/SN of rats. Pretreatment of the
animals with progressively higher but nontoxic doses of METH
caused complete protection against METH challenge-induced DA
depletion but partial protection against 5-HT depletion in the
striatum. In contrast, the pretreatment did not afford any
protection against METH-induced decreases in 5-HT levels in
the ventral midbrain. The observations on the protective effects of
METH preconditioning on drug-induced monoamine depletion
are consistent with those reported by several groups of
investigators (reviewed in [2]). In addition to the biochemical
data, microarray analyses revealed that METH preconditioning
was associated with METH challenge-induced transcriptional
responses that were substantially different from those observed in
the absence of drug preconditioning. The transcriptional profile in
response to METH preconditioning alone is characterized by
significant decreases in the expression of several transcripts (43 out
of 63 genes) that are involved in epigenetic phenomena,
neurotransmission and signal transduction, and transcriptional
regulation (see Table 1). These observations suggest that the latent
METH tolerant brain might be characterized by a state of
decreased metabolism associated with suppressed neurotransmis-
sion because 18 of 21 genes involved in metabolism, neurotrans-
mission and signal transduction were down-regulated by METH
preconditioning alone. This idea is consistent with clinical studies
that have reported that humans who abuse METH chronically
show decreased brain glucose metabolism [84,85]. Our additional
findings that pretreatment with progressively increasing nontoxic
amount of METH is associated with substantial alterations in the
transcriptional responses to an injurious METH challenge are
consistent with observations that brief ischemic events can also
change genomic responses to more prolonged ischemic injuries
[25,26,86]. These results suggest that neuroadaptive molecular
changes might serve a fundamental role in the survival of neurons
in organisms faced with an array of environmental toxic stressors
[87,88]. In what follows, we discuss the potential protective role of
differential changes in gene expression in the model of METH
preconditioning.
TRH was originally discovered as a hypothalamic neuropeptide
which is involved in the synthesis and release of thyrotropin for the
pituitary gland [89]. TRH is widely distributed in the brain [43]
and is important in the regulation of energy metabolism via effects
on feeding behaviors, locomotor activity and thermogenesis
[90,91]. A number of studies have indicated that TRH and some
analogs can provide significant neuroprotection in several models
of neurodegeneration. For example, TRH has been shown to
Figure 7. The METH challenge caused changes in the expression of antioxidant transcripts in the ventral midbrain of METH-
preconditioned rats. The METH challenge caused significant increases in (A) CuZnSOD, (B) MnSOD, (C) GPx, and (D) Hmox1 in the METH-
preconditioned group. Keys to statistics are shown in the legend to Fig. 4.
doi:10.1371/journal.pone.0007812.g007
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and the brain [93]. It has also been reported that TRH analogs
also provide significant beneficial effects against cerebral ischemia
[94,95]. TRH also provides neuroprotection against N-methyl-D-
aspartate (NMDA)-induced cell death in rat hippocampal slices
[96]. This discussion is also consistent with reports that TRH can
protect against kainate-induced neurotoxicity in rodents [97] and
glutamate-induced neuronal cell death [98]. Since ischemic or
pharmacological preconditioning provides significant protection in
these various models [27,64,99], it will be of interest to test
whether these preconditioning paradigms also cause increases in
TRH expression.
The expression of BDNF, a member of the neurotrophin family
of trophic factors that are involved in the developmental regulation
of cell survival and differentiation and in the mediation of synaptic
plasticity [100,101], was also affected differentially by the METH
challenge in the absence and presence of METH preconditioning.
TheincreasesintheBDNFtranscriptinthe METH-preconditioned
animals whichwere then injected with toxic dosesofMETH suggest
that the repeated injections of nontoxic doses of METH might have
primed the BDNF promoter, possibly via epigenetic modifications,
to such a degree that there were increased BDNF transcription only
after exposure to a toxic dose of the drug since there were no
changes in the BDNF transcript in the METH preconditioning only
group. The idea that the BDNF responses to METH precondition-
ing might be related to epigenetic changes is consistent with the
report that histone deacetylase (HDAC) inhibitors can cause
increases in BDNF transcription and protection of dopaminergic
neurons against cellular damage [102]. Moreover, the observations
that BDNF expression is related to decreases in CpG methylation in
the regulatory sequence of the BDNF gene [103] and that
developmental BDNF expression in the mouse brain is also
correlated with patterns of methylation at CpG sites within the
BDNF promoter [104] also support the idea that epigenetic
phenomena are very important to the regulation of BDNF
expression after METH preconditioning. The possibility exists,
nevertheless, that other mechanisms might be involved in BDNF
regulation. For example, we found that METH caused differential
c-fos expression in a manner that parallels the changes in BDNF
expression among the experimental groups. Members of the AP-1
family of transcription factors, especially c-fos, are induced in
several models of neuronal injuries [105,106]. BDNF is often
induced in the same models of brain injury [105,106], with BDNF
and c-fos being, oftentimes, co-induced in neurons after excitotoxic
damage [105]. Moreover, c-fos mutant knockout mice show altered
responses in BDNF expression after injections of the excitotoxin,
kainic acid [105,106]. Also of interest is the demonstration that
BDNF can induce c-fos expression in midbrain dopaminergic
neurons [107]. Thus, when taken together with our present data,
these observations suggest that the METH-induced increases in
BDNF expression observed after METH preconditioning might, in
part,besecondarytoMETH-inducedchangesinc-fosexpressionor
vice versa in such a manner as to form a feedback regulatory loop
that serves to provide long-term neuroprotection against METH-
induced injuries. The latter suggestion is consistent with our
previous observation that METH toxicity is exacerbated in the
brains of c-fos knockout mice [108]. This idea is also supported by
the report that induction of endogenous BDNF protects midbrain
DA neurons against kainate-induced transneuronal degeneration
[73]. It is also remarkable that BDNF has been reported to cause
upregulation of pre-pro-TRH in the fetal hypothalamus [109,110].
These observations suggest that BDNF might act through various
signaling mechanisms to protect the mesostriatal DA system against
the toxic effects of METH since TRH, a neuroprotective hormone
[92–96], showed large increases in the ventral midbrain of METH-
challenged rats in the presence of METH preconditioning.
Recent evidence has accumulated to suggest that some of the
protective effects of trophic factors, including BDNF, might be
mediated through inhibition of the deleterious effects of reactive
oxygen species (ROS) [111–113]. ROS including superoxide
radicals, hydrogen peroxide, and hydroxyl radicals are reactive
molecules that are produced during normal cellular processes
[114]. Their overproduction in the brain is thought to negatively
impact protein function, to cause lipid peroxidation, damage to
nucleic acids and to be involved in neurodegenerative processes
[114,115]. Almost immediately after the description of the toxic
effects of METH, it was suggested that METH-induced
monoamine depletion might be mediated by reactive species
generated during DA metabolism [116]. A role for superoxide
radicals was confirmed by the demonstration that METH toxicity
was attenuated in CuZnSOD transgenic mice [80,117]. Subse-
quent studies have shown that DA-generated quinones, which
trigger quinone cycling-dependent generation of superoxides and
hydrogen peroxide, are indeed involved in METH toxicity
[118,119]. Studies measuring lipid peroxidation, activity of
antioxidant enzymes, and formation of oxygen-based radicals
have confirmed a role for free radicals in the mediation of METH
toxicity [2,82]. Our observations of significant increases in
antioxidant transcripts suggest that repeated nontoxic oxidative
stress induced by METH preconditioning might have triggered
the development of a latent METH tolerance in striatal DA
terminals whose cell bodies are located in midbrain DA neurons
[120]. Moreover, the changes observed in antioxidant transcripts
in SN/VTA cell bodies might serve to supply antioxidant proteins
to scavenge METH-mediated DA-dependent reactive oxygen
species generated within monoaminergic cell bodies and terminals
[2,80]. Thus, working jointly with BDNF, c-fos, and HspB2,
increased transcription of these antioxidant genes might have
promoted a state of resistance to any further METH-induced
damage to the nigrostriatal DA system (see the schema in Fig. 8).
Also of interest are the increases in Hmox-1 expression observed
after the METH challenge in the METH preconditioned group.
Hmox-1 is a phase 2 enzyme that is induced by oxidative stress and
cellular injury [121,122]. METH causes its toxic effects, in part, by
causing oxidative stress [80,82]. The drug has recently been found to
increase Hmox-1 expression [33,83] and Hmox-1 induction protects
against METH-induced toxicity [83]. Thus, METH preconditioning
might be associated with modifications in the promoter of the Hmox-
1g e n ei nsu c haw a ya st ore n d e ri tm o r er e s p o n s i v et ot h ei n j e c t i o no f
METH doses that are known to cause oxidative stress-induced
injuries in the brain [2,79], with the increases in Hmox-1 expression
playing a significant role in the protection against METH-induced
DA depletion observed in the presence of METH preconditioning.
This suggestionis supported by the reports thatHmox-1 is involved in
the protection afforded by hyperbaric preconditioning of spinal cord
neurons [123] and by isoflurane preconditioning against glucose
deprivation [124]. It is also consistent with the observations that
Hmox-1 overexpression protects against 1-methyl-4-phenylpyridi-
nium-induced toxicity against dopaminergic neurons [125].
In summary, this is the first demonstration that prior repeated
injections of nontoxic doses of METH, which cause protection
against METH-induced striatal DA depletion in the rat, are also
associated with differential transcriptional responses to toxic METH
doses in the ventral midbrain of rats. These findings suggest that
METH preconditioning protects against striatal DA depletion, in
part, by suppressing injurious mechanisms while also augmenting
neuroprotective pathways in the nigrostriatal dopaminergic pathway.
Thus, the protective effects observed after METH preconditioning
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molecular pathway but on multiple endogenous protective systems
working in concert. Our observations further suggest that METH
preconditioning-induced transcriptional alterations might be the
results of epigenetic switches that affect promoter regions of genes in
such a way that changes in their transcriptional regulation become
manifest only in the presence of challenges with toxic doses of the
psychostimulant. Finally, because our results are consistent with
observations reported in models of brain preconditioning mediated
by ischemia or pharmacological agents, it will be of interest to test if
METH preconditioning might exert neuroprotective effects against
other models of neurodegeneration.
Materials and Methods
Animals
Male Sprague-Dawley rats (Charles Rivers Laboratories,
Raleigh, NC), weighing 330–370 g in the beginning of the
experiment were used in the present study. Animals were housed
in a humidity- and temperature-controlled room and were given
free access to food and water. All animal procedures were
performed according to the National Institutes of Health Guide for
the Care and Use of Laboratory Animals and were approved by the local
Animal Care Committee.
Drug Treatment and Tissue Collection
Following habituation, rats were injected intraperitoneally with
either (6)-METH-hydrochloride (NIDA, Baltimore, MD) or an
equivalent volume of 0.9% saline for a period of three weeks as
described in Table S1 in supplemental data. The saline- or
METH-pretreated animals received either saline or METH
(5 mg/kg68 at 1 h intervals) challenges 72 hours after the
preconditioning period. Similar doses of METH are known to
cause significant decreases in the levels of monoamines in the rat
striatum [12,18] which received dopaminergic terminals from
midbrain dopaminergic cell bodies located in the substantia nigra
(SN) and ventral tegmental area (VTA) [126,127]. Thus, the four
groups of animals were: saline/saline (SS), saline/METH (SM),
METH/saline (MS), and METH/METH (MM). The animals
were euthanized 24 h later by decapitation. Their brains were
quickly removed, striatal and SN/VTA tissues were dissected on
ice, snap frozen on dry ice, and stored at 280uC until used in
either HPLC, microarray analyses, or quantitative PCR experi-
ments as described below. One side of the brain was used for
HPLC and the other side for microarray and PCR experiments.
HPLC
For monoamine analysis, the brain regions were homogenized
in 0.01 M HClO4 and centrifuged at 14, 0006g for 15 min. DA,
3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid
(HVA), 5-HT and 5-hydroxyindoleacetic acid (5-HIAA) levels
were analyzed in the brain tissue extracts using HPLC with
electrochemical detector as previously described [128]. Mono-
amine levels are reported as pg/mg of tissue weight.
RNA extraction
Total RNA was isolated using Qiagen RNeasy Midi kit (Qiagen,
Valencia, CA) according to the manufacturer’s instructions. RNA
integrity was assessed using an Agilent 2100 Bioanalyzer (Agilent,
Palo Alto, CA) and showed no degradation.
Microarray hybridization and scanning
Microarray hybridization was carried out using Illumina’s
RatRef-12 Expression BeadChips arrays (22, 523 probes) (Illumina
Inc., San Diego, CA). In brief, a 600 ng aliquot of total RNA from
each striatal sample was amplified using Ambion’s Illumina RNA
Figure 8. Schematic rendering of potential pathways involved in METH preconditioning-induced protection on METH-induced
striatal DA depletion. The METH challenge caused substantial depletion of monoamines in the saline-pretreated animals. Repeated injections of
lower nontoxic doses of METH can cause repeated low levels of oxidative stress that are not toxic to cells. Moreover, repeated non-toxic oxidative
stress in the striatum and/or the ventral midbrain might trigger molecular mechanisms that generate a state of latent METH refractory brain that
provides protection against METH toxicity. The proposed tolerant state might occur through chronic METH-induced free radical-mediated epigenetic
changes and subsequent differential genomic responses to toxic doses of the drug.
doi:10.1371/journal.pone.0007812.g008
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stranded RNA (cRNA) was generated and labeled by incorporat-
ing biotin-16-UTP (Roche Diagnostics GmbH, Mannheim,
Germany, cat. no. 11388908910). 750 ng of each cRNA sample
were hybridized to Illumina arrays at 55uC overnight according to
the Illumina Whole-Genome Gene Expression Protocol for
BeadStation (Illumina Inc., San Diego, CA, cat. # 11201828).
Hybridized biotinylated cRNA was detected with Cyanine3-
streptavidin (Amersham Biosciences, Piscataway, NJ, cat.
#146065) and quantified using Illumina’s BeadStation 500GX
Genetic Analysis Systems scanner as described previously [33].
Microarray data analysis
The microarray data reported in the manuscript are in
accordance with MIAME guidelines. The raw data for the
analyses of the four groups of animals have been deposited in the
NCBI GEO database: Accession number GSE17665. The
Illumina BeadStudio software was used to measure fluorescent
hybridization signals. Data were extracted by BeadStudio
(Illumina, San Diego, CA) and then analyzed using GeneSpring
software v. 7.3.1 (Silicon Genetics, Redwood City, CA, USA).
Raw data were imported into GeneSpring and normalized using
global normalization. The normalized data were used to identify
changes in gene expression in these 3 group comparisons: MS vs
SS, SM vs SS, and MM vs MS. A gene was identified as changed if
it showed increased or decreased expression according to an
arbitrary cut-off of 1.7-fold changes at p,0.05.
Real-time PCR
Total RNA extracted from a midbrain region that encompasses
the ventral tegmental area and substantia nigra of the rat was used
to confirm the expression of genes of interest by real-time RT-
PCR as previously described [33]. In brief, individual total RNA
obtained from 5–7 rats per group was reverse-transcribed with
oligo dT primers and RT for PCR kit (Clontech, Palo Alto, CA).
PCR experiments were done using the Chroma4 RT-PCR
Detection System (BioRad Hercules, CA USA) and iQ SYBR
Green Supermix (BioRad) according to the manufacturer’s
protocol. Sequences for gene-specific primers corresponding to
PCR targets were obtained using LightCycler Probe Design
software (Roche). The primers were synthesized and HPLC-
purified at the Synthesis and Sequencing Facility of Johns Hopkins
University (Baltimore, MD). The list of primers is given in Table 4.
Quantitative PCR values were normalized using 18S rRNA and
quantified. The results are reported as relative changes which were
calculated as the ratios of normalized gene expression data of each
group compared to the SS group.
Statistical Analysis
Statistical analysis was performed using analysis of variance
(ANOVA) followed by Fisher’s protected least significant differ-
ence post-hoc comparison (StatView 4.02, SAS Institute, Cary,
NC). Values are shown as means 6 SEM. The null hypothesis was
rejected at p,0.05.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0007812.s001 (0.06 MB
DOC)
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